Total Payments
$362,123
2024 Payments
$152.28
Companies
29
Transactions
925
Medicare Patients
374
Medicare Billing
$233,883
Payment Breakdown by Category
Other$292,485 (80.8%)
Travel$54,956 (15.2%)
Food & Beverage$13,375 (3.7%)
Consulting$1,296 (0.4%)
Education$11.39 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $292,485 | 118 | 80.8% |
| Travel and Lodging | $54,956 | 301 | 15.2% |
| Food and Beverage | $13,375 | 502 | 3.7% |
| Consulting Fee | $1,296 | 1 | 0.4% |
| Education | $11.39 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $319,431 | 625 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $34,562 | 57 | $0 (2024) |
| Allergan Inc. | $4,020 | 15 | $0 (2019) |
| Bausch Health US, LLC | $826.01 | 74 | $0 (2021) |
| Sunovion Pharmaceuticals Inc. | $566.34 | 29 | $0 (2021) |
| Lundbeck LLC | $431.94 | 27 | $0 (2021) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $329.00 | 1 | $0 (2019) |
| Neuronetics, Inc. | $309.98 | 5 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $206.37 | 12 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $189.11 | 13 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $152.28 | 2 | Janssen Pharmaceuticals, Inc ($152.28) |
| 2023 | $131.38 | 2 | Axsome Therapeutics, Inc. ($110.00) |
| 2021 | $43,371 | 93 | Otsuka America Pharmaceutical, Inc. ($36,190) |
| 2020 | $17,740 | 90 | Otsuka America Pharmaceutical, Inc. ($12,926) |
| 2019 | $140,428 | 321 | Otsuka America Pharmaceutical, Inc. ($115,660) |
| 2018 | $73,347 | 200 | Otsuka America Pharmaceutical, Inc. ($72,775) |
| 2017 | $86,954 | 217 | Otsuka America Pharmaceutical, Inc. ($81,881) |
All Payment Transactions
925 individual payment records from CMS Open Payments — Page 1 of 37
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/19/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $133.41 | General |
| Category: Neuroscience | ||||||
| 03/06/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: Neuroscience | ||||||
| 09/27/2023 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: Neuroscience | ||||||
| 04/25/2023 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | Cash or cash equivalent | $110.00 | General |
| Category: Psychology/Psychiatric | ||||||
| 11/15/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,752.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $30.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $30.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $25.99 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $15.91 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $14.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $7.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/05/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $7.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $49.93 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $30.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $15.99 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $13.16 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $12.91 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $11.97 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $7.28 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Travel and Lodging | Cash or cash equivalent | $5.95 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $5.08 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $3.50 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $3.50 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $3.50 | General |
| Category: PSYCHIATRY | ||||||
| 10/29/2021 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $3.50 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 7 | 162 | 720 | $603,905 | $105,117 |
| 2020 | 7 | 212 | 1,024 | $354,525 | $128,766 |
Total Patients
374
Total Services
1,744
Medicare Billing
$233,883
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90868 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), subsequent delivery and management, per session | Office | 2021 | 19 | 517 | $516,610 | $82,821 | 16.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 62 | 107 | $21,450 | $8,846 | 41.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 25 | 39 | $9,750 | $5,125 | 52.6% |
| 90867 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), initial delivery and management | Office | 2021 | 16 | 16 | $26,050 | $3,067 | 11.8% |
| 90869 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), subsequent motor threshold re-determination with delivery and management | Office | 2021 | 15 | 16 | $24,120 | $2,784 | 11.5% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2021 | 12 | 12 | $3,000 | $1,567 | 52.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 13 | 13 | $2,925 | $906.74 | 31.0% |
| 90868 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), per session | Office | 2020 | 32 | 650 | $260,000 | $93,341 | 35.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 79 | 257 | $51,400 | $20,845 | 40.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 26 | 40 | $10,000 | $4,574 | 45.7% |
| 90867 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression) | Office | 2020 | 22 | 22 | $12,100 | $3,733 | 30.9% |
| 90869 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression) | Office | 2020 | 19 | 19 | $12,350 | $2,809 | 22.7% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2020 | 23 | 23 | $5,750 | $2,694 | 46.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 11 | 13 | $2,925 | $769.35 | 26.3% |
About Ranganathan Ram
Ranganathan Ram is a Psychiatry healthcare provider based in Wilmington, Delaware. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003846163.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Ranganathan Ram has received a total of $362,123 in payments from pharmaceutical and medical device companies, with $152.28 received in 2024. These payments were reported across 925 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($292,485).
As a Medicare-enrolled provider, Ram has provided services to 374 Medicare beneficiaries, totaling 1,744 services with total Medicare billing of $233,883. Data is available for 2 years (2020–2021), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Wilmington, DE
- Active Since 07/04/2006
- Last Updated 08/10/2021
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1003846163
Products in Payments
- REXULTI (Drug) $181,149
- ABILIFY MAINTENA (Drug) $129,190
- SPRAVATO (Drug) $34,535
- VRAYLAR (Drug) $4,055
- LATUDA (Drug) $566.34
- WELLBUTRIN (Drug) $500.19
- WELLBUTRIN XL (Drug) $345.64
- NeuroStar TMS Therapy (Device) $288.16
- BELSOMRA (Drug) $206.37
- Adzenys XR-ODT (Drug) $177.22
- TRINTELLIX (Drug) $141.01
- Trintellix (Drug) $132.15
- ARISTADA (Drug) $120.00
- Auvelity (Drug) $110.00
- APLENZIN (Drug) $90.41
- SUNOSI (Drug) $87.00
- ADHANSIA XR (Drug) $72.14
- VYVANSE (Drug) $69.97
- CAPLYTA (Drug) $63.55
- Fanapt (Drug) $59.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Wilmington
Dr. Paul Buongiorno, M.d, M.D
Psychiatry — Payments: $262,847
Psychiatry $262,847
Dr. Eric Christopher, M.d, M.D
Psychiatry — Payments: $89,218
Psychiatry $89,218
Dr. Manisha Wadhwa, M.d, M.D
Psychiatry — Payments: $71,032
Psychiatry $71,032
Sandeep Gupta, Md, MD
Psychiatry — Payments: $15,589
Psychiatry $15,589
Rano Mathew, Md, MD
Psychiatry — Payments: $13,650
Psychiatry $13,650
Dr. Brett Gurkin, M.d, M.D
Psychiatry — Payments: $9,247
Psychiatry $9,247